NO853769L - Fremgangsm¨te for regenerering av 6-fluor-4-kromanon fra 6 -fluor-4-ureidokroman-4-karboksylsyre. - Google Patents
Fremgangsm¨te for regenerering av 6-fluor-4-kromanon fra 6 -fluor-4-ureidokroman-4-karboksylsyre.Info
- Publication number
- NO853769L NO853769L NO853769A NO853769A NO853769L NO 853769 L NO853769 L NO 853769L NO 853769 A NO853769 A NO 853769A NO 853769 A NO853769 A NO 853769A NO 853769 L NO853769 L NO 853769L
- Authority
- NO
- Norway
- Prior art keywords
- fluoro
- acid
- carboxylic acid
- ureidochroman
- permanganate
- Prior art date
Links
- SWBBIJZMIGAZHW-UHFFFAOYSA-N 6-fluoro-2,3-dihydrochromen-4-one Chemical compound O1CCC(=O)C2=CC(F)=CC=C21 SWBBIJZMIGAZHW-UHFFFAOYSA-N 0.000 title claims abstract description 25
- 238000000034 method Methods 0.000 title claims description 44
- 238000011069 regeneration method Methods 0.000 title claims description 4
- 230000008929 regeneration Effects 0.000 title claims description 3
- 239000000203 mixture Substances 0.000 claims abstract description 40
- PLFOGGJHQOVQAF-LLVKDONJSA-N (4r)-4-(carbamoylamino)-6-fluoro-2,3-dihydrochromene-4-carboxylic acid Chemical compound C1=C(F)C=C2[C@@](NC(=O)N)(C(O)=O)CCOC2=C1 PLFOGGJHQOVQAF-LLVKDONJSA-N 0.000 claims abstract description 14
- 239000012286 potassium permanganate Substances 0.000 claims abstract description 12
- 239000002253 acid Substances 0.000 claims description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 33
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 31
- PLFOGGJHQOVQAF-UHFFFAOYSA-N 4-(carbamoylamino)-6-fluoro-2,3-dihydrochromene-4-carboxylic acid Chemical compound C1=C(F)C=C2C(NC(=O)N)(C(O)=O)CCOC2=C1 PLFOGGJHQOVQAF-UHFFFAOYSA-N 0.000 claims description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 17
- 229960000583 acetic acid Drugs 0.000 claims description 13
- 239000002904 solvent Substances 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 239000012362 glacial acetic acid Substances 0.000 claims description 8
- 229910052783 alkali metal Inorganic materials 0.000 claims description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- 150000001340 alkali metals Chemical class 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 claims description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 2
- 229910017604 nitric acid Inorganic materials 0.000 claims description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims 1
- 229940092714 benzenesulfonic acid Drugs 0.000 claims 1
- 229960000443 hydrochloric acid Drugs 0.000 claims 1
- 229940074355 nitric acid Drugs 0.000 claims 1
- 229960004838 phosphoric acid Drugs 0.000 claims 1
- 229940032330 sulfuric acid Drugs 0.000 claims 1
- LXANPKRCLVQAOG-NSHDSACASA-N sorbinil Chemical compound C12=CC(F)=CC=C2OCC[C@@]21NC(=O)NC2=O LXANPKRCLVQAOG-NSHDSACASA-N 0.000 abstract description 18
- 229950004311 sorbinil Drugs 0.000 abstract description 17
- 238000007254 oxidation reaction Methods 0.000 abstract description 13
- 230000003647 oxidation Effects 0.000 abstract description 12
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 8
- 238000004519 manufacturing process Methods 0.000 abstract description 7
- 239000006227 byproduct Substances 0.000 abstract description 4
- 229940118148 Aldose reductase inhibitor Drugs 0.000 abstract description 3
- 239000003288 aldose reductase inhibitor Substances 0.000 abstract description 3
- 230000001684 chronic effect Effects 0.000 abstract description 3
- MNQZXJOMYWMBOU-UHFFFAOYSA-N glyceraldehyde Chemical compound OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 abstract description 2
- 230000004048 modification Effects 0.000 abstract 2
- 238000012986 modification Methods 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
- 239000002002 slurry Substances 0.000 description 18
- 239000007787 solid Substances 0.000 description 16
- 238000001914 filtration Methods 0.000 description 15
- 239000000758 substrate Substances 0.000 description 15
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- MSTDXOZUKAQDRL-UHFFFAOYSA-N 4-Chromanone Chemical compound C1=CC=C2C(=O)CCOC2=C1 MSTDXOZUKAQDRL-UHFFFAOYSA-N 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- KWGRBVOPPLSCSI-WPRPVWTQSA-O (-)-ephedrinium Chemical compound C[NH2+][C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-O 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- -1 bicyclic ketone Chemical class 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- PLFOGGJHQOVQAF-NSHDSACASA-N (4s)-4-(carbamoylamino)-6-fluoro-2,3-dihydrochromene-4-carboxylic acid Chemical compound C1=C(F)C=C2[C@](NC(=O)N)(C(O)=O)CCOC2=C1 PLFOGGJHQOVQAF-NSHDSACASA-N 0.000 description 7
- 150000001412 amines Chemical class 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 239000002535 acidifier Substances 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- LXANPKRCLVQAOG-UHFFFAOYSA-N 6-fluorospiro[2,3-dihydrochromene-4,5'-imidazolidine]-2',4'-dione Chemical compound C12=CC(F)=CC=C2OCCC21NC(=O)NC2=O LXANPKRCLVQAOG-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 239000012452 mother liquor Substances 0.000 description 4
- 239000012429 reaction media Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- GKKCIDNWFBPDBW-UHFFFAOYSA-M potassium cyanate Chemical compound [K]OC#N GKKCIDNWFBPDBW-UHFFFAOYSA-M 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- RQEUFEKYXDPUSK-SSDOTTSWSA-N (1R)-1-phenylethanamine Chemical class C[C@@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-SSDOTTSWSA-N 0.000 description 2
- FATKFOJBJPZZED-UHFFFAOYSA-N 4-amino-6-fluoro-2,3-dihydrochromene-4-carboxylic acid Chemical compound C1=C(F)C=C2C(N)(C(O)=O)CCOC2=C1 FATKFOJBJPZZED-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 2
- 208000002230 Diabetic coma Diseases 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 239000005909 Kieselgur Substances 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 150000001342 alkaline earth metals Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- ZUDYPQRUOYEARG-UHFFFAOYSA-L barium(2+);dihydroxide;octahydrate Chemical compound O.O.O.O.O.O.O.O.[OH-].[OH-].[Ba+2] ZUDYPQRUOYEARG-UHFFFAOYSA-L 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 229940091173 hydantoin Drugs 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 1
- KWGRBVOPPLSCSI-PSASIEDQSA-N (1s,2r)-2-(methylamino)-1-phenylpropan-1-ol Chemical class CN[C@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-PSASIEDQSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 description 1
- SIWNEELMSUHJGO-UHFFFAOYSA-N 2-(4-bromophenyl)-4,5,6,7-tetrahydro-[1,3]oxazolo[4,5-c]pyridine Chemical compound C1=CC(Br)=CC=C1C(O1)=NC2=C1CCNC2 SIWNEELMSUHJGO-UHFFFAOYSA-N 0.000 description 1
- JYLNVJYYQQXNEK-UHFFFAOYSA-N 3-amino-2-(4-chlorophenyl)-1-propanesulfonic acid Chemical compound OS(=O)(=O)CC(CN)C1=CC=C(Cl)C=C1 JYLNVJYYQQXNEK-UHFFFAOYSA-N 0.000 description 1
- WEEYACRTXKADQT-UHFFFAOYSA-N 4-(carbamoylamino)-2-fluoro-2,3-dihydrochromene-4-carboxylic acid Chemical compound FC1OC2=CC=CC=C2C(C1)(C(=O)O)NC(=O)N WEEYACRTXKADQT-UHFFFAOYSA-N 0.000 description 1
- 102000016912 Aldehyde Reductase Human genes 0.000 description 1
- 108010053754 Aldehyde reductase Proteins 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 229920002396 Polyurea Polymers 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000025938 carbohydrate utilization Effects 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910002096 lithium permanganate Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
- 229940125395 oral insulin Drugs 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 239000004289 sodium hydrogen sulphite Substances 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/42—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4
- C07D311/44—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4 with one hydrogen atom in position 3
- C07D311/54—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4 with one hydrogen atom in position 3 substituted in the carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/68—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with nitrogen atoms directly attached in position 4
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrane Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Jellies, Jams, And Syrups (AREA)
- Control And Safety Of Cranes (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Manufacture, Treatment Of Glass Fibers (AREA)
- Fats And Perfumes (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/655,006 US4551542A (en) | 1984-09-26 | 1984-09-26 | Regeneration of 6-fluoro-4-chromanone from 6-fluoro-4-ureidochroman-4-carboxylic acid |
| CN85106603.8A CN1004000B (zh) | 1984-09-26 | 1985-08-31 | 由6-氟代-4-脲基苯并二氢吡喃-4-羧酸再生为6-氟代苯并二氢吡喃-4-酮的方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO853769L true NO853769L (no) | 1986-04-01 |
Family
ID=76224744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO853769A NO853769L (no) | 1984-09-26 | 1985-09-25 | Fremgangsm¨te for regenerering av 6-fluor-4-kromanon fra 6 -fluor-4-ureidokroman-4-karboksylsyre. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US4551542A (da) |
| EP (1) | EP0179570B1 (da) |
| JP (1) | JPS6185376A (da) |
| KR (1) | KR870000584B1 (da) |
| CN (1) | CN1004000B (da) |
| AT (1) | ATE36158T1 (da) |
| AU (1) | AU554303B2 (da) |
| CA (1) | CA1215378A (da) |
| DD (1) | DD239594A5 (da) |
| DE (1) | DE3564111D1 (da) |
| DK (1) | DK433685A (da) |
| ES (1) | ES8604848A1 (da) |
| FI (1) | FI853684L (da) |
| GR (1) | GR852286B (da) |
| HU (1) | HU196387B (da) |
| IL (1) | IL76488A (da) |
| NO (1) | NO853769L (da) |
| PH (1) | PH20691A (da) |
| PL (1) | PL147214B1 (da) |
| PT (1) | PT81184B (da) |
| SU (1) | SU1340586A3 (da) |
| YU (1) | YU43885B (da) |
| ZA (1) | ZA857379B (da) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11498018B2 (en) * | 2017-11-27 | 2022-11-15 | Vasilios (Bill) Panagiotakopoulos | Extraction and purification of cannabinoid compounds |
| CN112939793B (zh) * | 2021-02-03 | 2022-07-08 | 浙江普洛康裕制药有限公司 | 麻黄碱和伪麻黄碱工业生产过程中母液中活性成分的回收利用方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4117230A (en) * | 1976-10-18 | 1978-09-26 | Pfizer Inc. | Hydantoin derivatives as therapeutic agents |
| US4147795A (en) * | 1977-02-11 | 1979-04-03 | Pfizer Inc. | Hydantoin derivatives as therapeutic agents |
| US4130714A (en) * | 1977-05-23 | 1978-12-19 | Pfizer Inc. | Hydantoin therapeutic agents |
| US4210663A (en) * | 1978-11-08 | 1980-07-01 | Pfizer Inc. | Halogen substituted benzopyran- and benzothiopyran-4-carboxylic acids |
| US4286098A (en) * | 1980-03-28 | 1981-08-25 | Pfizer Inc. | Process for the preparation of chiral hydantoins |
| US4348526A (en) * | 1980-03-28 | 1982-09-07 | Pfizer Inc. | Intermediates in the preparation of chiral hydantoins |
| DE3262294D1 (en) * | 1981-05-13 | 1985-03-28 | Ici Plc | Pharmaceutical compositions containing spiro succinimide derivatives |
| US4435578A (en) * | 1982-11-10 | 1984-03-06 | Pfizer Inc. | Sorbinil by optical resolution of precursor 6-fluoro-4-ureidochroman-4-carboxylic acid |
| US4431828A (en) * | 1982-11-10 | 1984-02-14 | Pfizer Inc. | Regeneration of 6-fluoro-4-chromanone from by-products in the synthesis of sorbinil |
-
1984
- 1984-09-26 US US06/655,006 patent/US4551542A/en not_active Expired - Lifetime
-
1985
- 1985-06-27 CA CA000485501A patent/CA1215378A/en not_active Expired
- 1985-08-31 CN CN85106603.8A patent/CN1004000B/zh not_active Expired
- 1985-09-19 GR GR852286A patent/GR852286B/el unknown
- 1985-09-23 DE DE8585306741T patent/DE3564111D1/de not_active Expired
- 1985-09-23 EP EP85306741A patent/EP0179570B1/en not_active Expired
- 1985-09-23 AT AT85306741T patent/ATE36158T1/de not_active IP Right Cessation
- 1985-09-24 PL PL1985255500A patent/PL147214B1/pl unknown
- 1985-09-24 IL IL76488A patent/IL76488A/xx unknown
- 1985-09-24 DD DD85280951A patent/DD239594A5/de not_active IP Right Cessation
- 1985-09-24 ES ES547256A patent/ES8604848A1/es not_active Expired
- 1985-09-24 PT PT81184A patent/PT81184B/pt unknown
- 1985-09-25 AU AU47884/85A patent/AU554303B2/en not_active Ceased
- 1985-09-25 DK DK433685A patent/DK433685A/da not_active Application Discontinuation
- 1985-09-25 KR KR1019850007042A patent/KR870000584B1/ko not_active IP Right Cessation
- 1985-09-25 HU HU853644A patent/HU196387B/hu not_active IP Right Cessation
- 1985-09-25 SU SU853952444A patent/SU1340586A3/ru active
- 1985-09-25 FI FI853684A patent/FI853684L/fi not_active IP Right Cessation
- 1985-09-25 PH PH32850A patent/PH20691A/en unknown
- 1985-09-25 ZA ZA857379A patent/ZA857379B/xx unknown
- 1985-09-25 YU YU1531/85A patent/YU43885B/xx unknown
- 1985-09-25 NO NO853769A patent/NO853769L/no unknown
- 1985-09-26 JP JP60213619A patent/JPS6185376A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| PL255500A1 (en) | 1986-07-15 |
| CN85106603A (zh) | 1987-03-18 |
| HUT38624A (en) | 1986-06-30 |
| ES8604848A1 (es) | 1986-02-16 |
| KR870000584B1 (ko) | 1987-03-23 |
| PT81184B (en) | 1987-07-31 |
| HU196387B (en) | 1988-11-28 |
| IL76488A0 (en) | 1986-01-31 |
| DK433685A (da) | 1986-03-27 |
| AU554303B2 (en) | 1986-08-14 |
| FI853684L (fi) | 1986-03-27 |
| DK433685D0 (da) | 1985-09-25 |
| PT81184A (en) | 1985-10-01 |
| ZA857379B (en) | 1987-05-27 |
| PH20691A (en) | 1987-03-24 |
| JPS6185376A (ja) | 1986-04-30 |
| ATE36158T1 (de) | 1988-08-15 |
| GR852286B (da) | 1986-01-21 |
| US4551542A (en) | 1985-11-05 |
| IL76488A (en) | 1989-07-31 |
| DD239594A5 (de) | 1986-10-01 |
| YU153185A (en) | 1987-12-31 |
| FI853684A0 (fi) | 1985-09-25 |
| EP0179570B1 (en) | 1988-08-03 |
| YU43885B (en) | 1989-12-31 |
| CA1215378A (en) | 1986-12-16 |
| SU1340586A3 (ru) | 1987-09-23 |
| CN1004000B (zh) | 1989-04-26 |
| KR860002509A (ko) | 1986-04-26 |
| ES547256A0 (es) | 1986-02-16 |
| DE3564111D1 (en) | 1988-09-08 |
| AU4788485A (en) | 1986-04-10 |
| PL147214B1 (en) | 1989-05-31 |
| EP0179570A1 (en) | 1986-04-30 |
| JPH0225908B2 (da) | 1990-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI62838C (fi) | Foerfarande foer framstaellning av den nya farmaceutiskt anvaendbara hoegerroterande isomeren av en asymmetriskt spiro-hydantoinfoerening | |
| CN112592312B (zh) | 一种托吡卡胺的制备方法 | |
| NO148453B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive spirohydantoinderivater | |
| NO166164B (no) | Festeanordning til aa etablere elektrisk forbindelse med en engangs hudelektrode. | |
| NO119800B (da) | ||
| NO853769L (no) | Fremgangsm¨te for regenerering av 6-fluor-4-kromanon fra 6 -fluor-4-ureidokroman-4-karboksylsyre. | |
| CN112457181A (zh) | 一种d-泛酸钙的合成方法 | |
| CN110483498A (zh) | 一种他唑巴坦中间体的制备方法 | |
| CN112279817B (zh) | 一种高纯度盐酸普拉克索的制备方法 | |
| CN111349075A (zh) | 一种琥珀酸曲格列汀的制备方法 | |
| JPS63211278A (ja) | Ｓ−６−フルオル−４−ウレイドクロマン−４−カルボン酸のアミン塩およびその製法 | |
| NZ213594A (en) | Regeneration of 6-fluoro-4-chromanone from 6-fluoro-4-ureidochroman-4-carboxylic acid | |
| NO168773B (no) | Fremgangsmaate for spaltning av racemiske spiro-hydantoiner | |
| CN110903247B (zh) | 一种大幅降低奥芬达唑杂质b的制备方法 | |
| Dakin | CLI.—The fractional hydrolysis of amygdalinic acid. iso Amygdalin | |
| NO853305L (no) | Chirale kromanforbindelser og fremgangmsmaate for fremstilling av sorbinil ved hjelp derav. | |
| JPH0348674A (ja) | 新規なクマリン誘導体，その製法及び用途 | |
| CN116217440A (zh) | 一种西他列汀关键中间体的制备方法 | |
| CN111377879A (zh) | 一种l-噻唑烷-4-甲酸的制备方法 | |
| WO2001057007A1 (fr) | Sel de metal alcalin de derive de thiazolidine-4,4-dione | |
| JPS63264455A (ja) | ４−［３−（イソプロピルアミノ）−２−ヒドロキシプロポキシ］−インドールの製造方法 | |
| JPH01168667A (ja) | ４−ヒドロキシインドリンの製造法 | |
| NO790281L (no) | Fremgangsmaate til fremstilling av spesifikke, optiske isomere. | |
| CH287476A (fr) | Procédé de préparation de l'acide 4-amino-9-méthyl-ptéroyl-glutamique. | |
| JPS6410496B2 (da) |